Heart defect closure device market to reach $2.36 billion by 2030

The Business Research Company projects the global heart defect closure device market will grow from $1.27 billion in 2025 to $1.45 billion in 2026, then climb to $2.36 billion by 2030. Growth is being driven by more congenital heart defects, wider use of minimally invasive procedures and faster adoption of transcatheter cardiac interventions.

Why it matters: - The heart defect closure device market is expanding as hospitals and cardiac centers shift toward less invasive treatment options. - Rising demand matters because these devices can close structural heart openings without open-heart surgery, which can lower procedural risk and broaden treatment access. - The market’s growth also signals a larger addressable patient base tied to congenital and structural heart disease.

What happened: - The Business Research Company released its Heart Defect Closure Device Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report estimates the market will rise from $1.27 billion in 2025 to $1.45 billion in 2026. - The report projects the market will reach $2.36 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period. - The report also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa in its regional analysis. - A free sample of the report is available here. - The full report is available here.

The details: - Heart defect closure devices are medical tools designed to seal abnormal openings in the heart, most often in the septum. - The devices are used for atrial septal defects and patent foramen ovale. - The products are delivered through minimally invasive procedures. - The report links near-term growth to a 14.5% CAGR from 2025 to 2026. - It projects a 12.9% CAGR through 2030. - Historical growth has been supported by more congenital heart defects, advances in interventional cardiology, higher awareness of septal defect treatment, growth in cardiac catheterization labs and demand for minimally invasive cardiac procedures. - Future growth is expected to come from older and pediatric patients with structural heart abnormalities, broader use of transcatheter cardiac interventions, higher cardiovascular spending, more specialized cardiac centers and earlier diagnosis and treatment. - Key trends include more use of minimally invasive transcatheter closure techniques. - The market is also shifting toward nitinol-based and self-expanding closure devices. - The report expects continued movement away from open-heart surgery and toward device-based alternatives. - Structural heart disease treatment programs are expanding. - Device safety, efficacy and long-term patient outcomes remain active development priorities.

Between the lines: - The forecast points to a market shaped by both clinical need and technology adoption. - More awareness among patients and providers can lift diagnosis rates, which in turn can expand device use. - The regional split suggests the U.S. and other developed markets still anchor revenue, while emerging Asian markets may deliver faster volume growth. - A cited August 2025 projection from the National Center for Biotechnology Information says cardiovascular disease prevalence could rise 90% between 2025 and 2050, with deaths climbing to 35.6 million by 2050 from 20.5 million in 2025. - That same projection estimates crude mortality will increase 73.4% and DALYs will rise 54.7% over the period.

What's next: - Adoption of transcatheter closure procedures is likely to deepen as more centers build structural heart programs. - Device makers are expected to keep pushing materials and design improvements aimed at safety and durability. - Market growth will likely stay tied to early detection, healthcare spending and access to advanced cardiac care.

The bottom line: - Heart defect closure devices are moving from a niche cardiovascular segment to a broader minimally invasive treatment category, and the market outlook remains strong through 2030.